On Thursday, November 12, NovaBay Pharmaceuticals NBY will report its last quarter's earnings. Here is Benzinga's preview of the company's release.
Net Income, Earnings, And Earnings Per Share
Earnings and especially earnings per share (EPS) are useful measures of a company's profitability. Total earnings, which is also referred to as net income, equals total revenue minus total expenses. EPS equals to net income divided by the number of shares outstanding.
Earnings And Revenue
NovaBay Pharmaceuticals EPS loss is expected to be around $0.04, according to sell-side analysts. Sales will likely be near $2.52 million. NovaBay Pharmaceuticals EPS in the same period a year ago totaled $0.02. Sales were $1.61 million.
Why Analyst Estimates And Earnings Surprises Are Important
Analysts who cover this company will publish forward-looking estimates of its revenue and EPS each quarter. Averaging together every EPS and revenue prediction that each analyst makes about a company in a quarter yields the "consensus estimates." A company posting earnings or revenue above or below the consensus estimate is known as an "earnings surprise" and may move the stock by a considerable margin.
The analyst consensus estimate would represent a 100.0% decline in the company's EPS figure. Revenue would be have grown 56.04% from the same quarter last year. NovaBay Pharmaceuticals's reported EPS has stacked up against analyst estimates in the past like this:
|Quarter||Q2 2020||Q1 2020||Q4 2020||Q3 2019|
|Revenue Estimate||2.85 M||2.09 M||2.07 M||2.05 M|
|Revenue Actual||3.98 M||1.89 M||1.70 M||1.61 M|
Shares of NovaBay Pharmaceuticals were trading at $0.583 as of November 10. Over the last 52-week period, shares are up 6.33%. Given that these returns are generally positive, long-term shareholders can be satisfied going into this earnings release.
Do not be surprised to see the stock move on comments made during its conference call. NovaBay Pharmaceuticals is scheduled to hold the call at 16:30:00 ET and can be accessed here.
© 2022 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.